Spots Global Cancer Trial Database for Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
Official Title: Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
Study ID: NCT05856409
Interventions
Study Description
Brief Summary: This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.
Detailed Description: Gallium 68-labeled fibroblast-activation protein inhibitor (68Ga-FAPI) has recently been a potential radiotracer for gynecological malignancies,including ovarian cancer. Early detection and localization of sites of recurrence helps to identify ovarian cancer patients who will benefit the most from secondary surgery, chemotherapy, or radiation therapy. Its clinical utility for recurrence detection of epithelial ovarian cancer and histological validation of FAPI findings is not well established.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Contact Details
Name: Jianjun Liu, PH.D
Affiliation: Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
